Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDOLAS Study
2024-518909-18-00Phase 3Authorised
- Sponsor
- Società Italiana Malattie Infettive e Tropicali
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Società Italiana Malattie Infettive e Tropicali. Primary endpoint: Proportion of participants with virological rebound at week 48. Planned start Dec 2024; status: authorised.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-518909-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518909-18-00.